Paul Holvoet
Impact in
- Biochemistry top 0.1%
- Antioxidant Activity and Oxidative Stress
- Cancer Research top 0.5%
- MicroRNA in disease regulation
- Protease and Inhibitor Mechanisms
Papers in
- Biochemistry 33
- Antioxidant Activity and Oxidative Stress 33
-
- Protease and Inhibitor Mechanisms 18
- Co-authors
- Désiré CollenMaarten HulsmansAnn MertensD CollenFrans Van de WerfJohan VanhaeckeDieuwke De KeyzerS. Janssens
- Journals
- Circulation (16 papers)Arteriosclerosis Thrombosis and Vascular Biology (14 papers)Thrombosis and Haemostasis (14 papers)Journal of Biological Chemistry (9 papers)Atherosclerosis (7 papers)
- Partner nations
- BelgiumUnited StatesFrance
In The Last Decade
Paul Holvoet
173 papers receiving 11.6k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Biochemistry 1.7k
- Cancer Research 1.9k
- Clinical Biochemistry 760
- Immunology 2.2k
- Endocrinology, Diabetes and Metabolism 1.7k
Countries citing papers authored by Paul Holvoet
This map shows the geographic impact of Paul Holvoet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Holvoet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Holvoet more than expected).
Fields of papers citing papers by Paul Holvoet
This network shows the impact of papers produced by Paul Holvoet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Holvoet. The network helps show where Paul Holvoet may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Holvoet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 3 | |
| 2 | 2021 | 21 | |
| 3 | 2016 | 79 | |
| 4 | 2011 | 41 | |
| 5 | 2011 | 37 | |
| 6 | 2009 | 12 | |
| 7 | 2008 | 260 | |
| 8 | 2007 | 45 | |
| 9 | Quantitation and distribution of lipoprotein-associated phospholipase A(2) and oxidized low density lipoprotein in atherosclerotic lesions of carotid endarterectomy tissues | 2006 | 1 |
| 10 | Recullarisation of photo-oxidised pericardium using immature foreign body reaction in the construction of a tissue engineered heart valve | 2004 | 3 |
| 11 | Recovery of endothelial function and coronary plaque stabilisation after lipid lowering in LDL-hypercholesterolaemic pigs | 2001 | 2 |
| 12 | Intramural and intrapulmonary injection of chlamydia pneumoniae leads to coronary artery intimal proliferation in normal pigs | 2000 | 2 |
| 13 | Human-like HDL -in vivo- reduces oxidative stress, Ca2+ transients, adhesion molecule expression and macrophage homing in apoE deficient mice | 1999 | 3 |
| 14 | Promoter dependence of persistence of the effect of the human apo E enhancer on human apolipoprotein A-I expression after adenoviral gene transfer is partially explained by promoter attenuation | 1999 | 1 |
| 15 | Effects of deletion or substitution of the carboxyterminal domain of human apolipoprotein A-I on high density lipoprotein metabolism in transgenic mice | 1996 | 1 |
| 16 | Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients | 1995 | 8 |
| 17 | Effects of fibrin-targeting and clearance rate on the thrombolytic potency of chimeric plasminogen activators consisting of a single-chain Fv fragment derived from a fibrin-specific antibody and single-chain u-PA (scu-PA) | 1992 | 3 |
| 18 | Thrombolytic properties of a recombinant humanized antifibrin antibody/urokinase-type plasminogen activator chimera | 1992 | 1 |
| 19 | CHARACTERIZATION OF A SINGLE-CHAIN RECOMBINANT PLASMINOGEN-ACTIVATOR CONSISTING OF A FV FRAGMENT DERIVED FROM A D-DIMER SPECIFIC ANTIBODY AND LOW-MOLECULAR-WEIGHT SINGLE-CHAIN UROKINASE (RSCU-PA-32K) | 1991 | 3 |
| 20 | MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE FIBRIN-BINDING SITE OR THE ACTIVE-SITE OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) | 1985 | 3 |
About Paul Holvoet
Paul Holvoet is a scholar working on Biochemistry, Cancer Research, Internal Medicine, Immunology and Cardiology and Cardiovascular Medicine, having authored 174 papers that have together received 12.0k indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (33 papers), Antioxidant Activity and Oxidative Stress (33 papers), Lipoproteins and Cardiovascular Health (26 papers), Adipokines, Inflammation, and Metabolic Diseases (22 papers), Adipose Tissue and Metabolism (20 papers), Protease and Inhibitor Mechanisms (18 papers), Cardiovascular Disease and Adiposity (16 papers) and Blood properties and coagulation (15 papers). The work is most often cited by research in Biochemistry (1.7k citations), Cancer Research (1.9k citations), Clinical Biochemistry (760 citations), Immunology (2.2k citations) and Endocrinology, Diabetes and Metabolism (1.7k citations). Paul Holvoet has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Désiré Collen, Maarten Hulsmans, Ann Mertens, D Collen, Frans Van de Werf, Johan Vanhaecke, Dieuwke De Keyzer, Désiré Collen, S. Janssens and Tamara B. Harris. Their work appears in journals such as Circulation, Arteriosclerosis Thrombosis and Vascular Biology, Thrombosis and Haemostasis, Journal of Biological Chemistry and Atherosclerosis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.